The overall hypothesis to be tested in this proposal is that RNA interference can be developed as a therapeutic modality for HIV-1 disease. RNA interference is a highly evolutionary conserved cellular mechanism whereby small double stranded RNAs induce specific silencing of genes. It is becoming increasingly clear that RNA interference plays a critical role in the regulation of cellular gene expression as well as protection from viruses, most clearly established in plants, and control of retrotransposition. Because RNAi is readily adaptable for knockdown of gene expression any gene for experimental purposes, RNA interference has been proposed as a therapeutic means to inhibit viral replication, including that of HIV-1. During the past funding period of this grant, we successfully developed shRNAs to downregulate CCR5 as a means to inhibit HIV-1 infection. We demonstrated that these shRNAs can downregulate CCR5 in primary T-cells in vitro, and protect cells from HIV-1 infection. As outlined in this proposal, the path towards developing an effective CCR5 shRNA was not straightforward, since it was recognized by ourselves and others in the field that RNAi related toxicity is a major hurdle to in vivo applications, such as HIV-1 disease, where long term expression is essential. Nevertheless, we have successfully overcome these obstacles and developed one shRNA that results in stable downregulation of CCR5.

Public Health Relevance

Relevance RNA interference is a means to block the function of genes. We will investigate whether RNA interference can be used as a potential therapy for HIV-1 disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI055281-06A2
Application #
7622474
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Voulgaropoulou, Frosso
Project Start
2003-03-01
Project End
2011-04-30
Budget Start
2009-05-05
Budget End
2010-04-30
Support Year
6
Fiscal Year
2009
Total Cost
$385,000
Indirect Cost
Name
University of California Los Angeles
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095